Scarica l'app Stockscreener
13.33
0.97%
-0.13
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? - MSN
What drives Cartesian Therapeutics Inc. stock priceOutstanding trading profits - PrintWeekIndia
Is Cartesian Therapeutics Inc. stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com
When is the best time to buy Cartesian Therapeutics Inc. stockBreakthrough capital growth - jammulinksnews.com
Is Cartesian Therapeutics Inc. a good long term investmentHigh-profit stock alerts - Autocar Professional
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate - Benzinga
Cartesian Therapeutics Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
Chronic Refractory Gout Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Amgen, Cartesian Therapeutics, Swedish Orphan Biovitrum, Arthrosi Therapeutics, TaiwanJ Pharma - Barchart.com
What analysts say about Cartesian Therapeutics Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
What makes Cartesian Therapeutics Inc. stock price move sharplyFree Stock Market Swing Trading Strategies - Newser
Multiple Myeloma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics - MenaFN
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityShort Squeeze Radar - Newser
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $40.00 Average Price Target from Analysts - Defense World
What is Wedbush’s Estimate for RNAC Q2 Earnings? - Defense World
Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis - TipRanks
Wedbush Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
CartesianAutoimmune Cell Therapy Excites, But Reality Bites (NASDAQ:RNAC) - Seeking Alpha
CAR T-Cell Therapies at a Crossroads: LICATS Challenges and the Rise of Cartesian Therapeutics in Autoimmune Markets - AInvest
Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating - Investing.com Canada
Cartesian stock up as Wedbush becomes bullish (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics' 15min chart sees KDJ Golden Cross, bullish Marubozu formation. - AInvest
AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition - insights.citeline.com
What caused RNAC's earnings to miss forecasts in Q4 2023? - AInvest
Rhumbline Advisers Grows Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance
Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail
IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail
Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa
Cartesian Therapeutics holds annual stockholders meeting - Investing.com
Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):